RECRUITING

Blood Samples for the Study of Peanut, Tree Nut and Other Food Allergies

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Food allergies are now a major problem. These experiments involve getting blood from people with food allergies and from people without food allergies. The blood collected will be used to answer questions and find information about peanut and other food allergies. Samples will come from: * People signed up by the investigators at the University of Colorado Denver * University of North Carolina, Massachusetts General Hospital, Children's Hospital of Colorado and the Immune Tolerance Network (Benaroya Research Institute) where people have been treated for peanut allergies * University of North Carolina, Massachusetts General Hospital, National Jewish Health and The Children's Hospital in Denver where people have taken part or will take part in clinically indicated oral food challenges. Blood and health histories from the University of North Carolina, Massachusetts General Hospital, National Jewish Health, The Children's Hospital and the Immune Tolerance Network will not have personal information linked. The specific aims of this experiment are: 1. Come up with a lab test that will predict how bad an allergic reaction will be to peanuts. 2. Find out what part of a peanut causes allergic reactions. 3. Come up with preventions that can block peanut allergies. 4. Find the strongest proteins in walnuts.

Official Title

Blood Samples for the Study of Peanut, Tree Nut and Other Food Allergies

Quick Facts

Study Start:2014-02
Study Completion:2030-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT02192866

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:1 Year to 75 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. De-identified sera or plasma from patients who have undergone Oral ImmunoTherapy (OIT) for peanut allergy. These samples already exist.
  2. *
  1. 1. Any known significant medical or psychiatric diagnosis
  2. 2. Use of an investigational drug within 30 days
  3. 3. Use of omalizumab (anti-IgE; Xolair) within 6 months

Contacts and Locations

Study Contact

Stephen Dreskin, MD, PhD
CONTACT
303-724-7190
Stephen.Dreskin@ucdenver.edu

Principal Investigator

Stephen Dreskin, MD, PhD
PRINCIPAL_INVESTIGATOR
University of Colorado, Denver

Study Locations (Sites)

University of Colorado School of Medicine
Denver, Colorado, 80045
United States

Collaborators and Investigators

Sponsor: University of Colorado, Denver

  • Stephen Dreskin, MD, PhD, PRINCIPAL_INVESTIGATOR, University of Colorado, Denver

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2014-02
Study Completion Date2030-12

Study Record Updates

Study Start Date2014-02
Study Completion Date2030-12

Terms related to this study

Additional Relevant MeSH Terms

  • Peanut Allergies
  • Tree Nut Allergies
  • Other Food Allergies